Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioNexus Gene Lab Corp ( (BGLC) ) has shared an update.
On December 24, 2025, BioNexus Gene Lab Corp. held its 2025 Annual Meeting of Stockholders, where shareholders elected four directors, Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, and Chee Keong Yap, to serve until the next annual meeting or until their successors are elected and qualified. At the same meeting, stockholders approved the company’s 2025 Equity Incentive Plan, ratified the appointment of JP Centurion & Partners PLT as independent registered public accounting firm for the fiscal year ending December 31, 2025, and authorized a potential adjournment of the meeting to solicit additional proxies if necessary, signaling solid shareholder support for the company’s governance and compensation framework.
More about BioNexus Gene Lab Corp
Average Trading Volume: 139,726
Technical Sentiment Signal: Sell
Current Market Cap: $7.44M
See more data about BGLC stock on TipRanks’ Stock Analysis page.